



A tool for investigation of  
Sabin Like 2 (SL2) poliovirus  
isolation in human or  
in the environment

WHO Geneva  
8 March 2017



**COUNTRY:** \_\_\_\_\_

## Investigation of Sabin2 Positive AFP Case, Healthy Person or Environmental Sample Site

**The National authority should initiate the detailed investigation within 48 hours of receipt of the notification of SL2 from the laboratory**

**NOTE:**

- Use dd/mm/yyyy format for date
- This form/report should be sent to the National EPI manager / WHO EPI medical officer or as decided by the country team

## Investigation team

No	Name	Organization	Contact address
1			
2			
3			
4			
5			
6			
7			

Date laboratory report received: \_\_\_\_\_

Date investigation started: \_\_\_\_\_

Date investigation completed: \_\_\_\_\_

Date report submitted: \_\_\_\_\_

## 1. Location of the case /contact /healthy person/ES site

Province or State or admin1 equivalent area: \_\_\_\_\_

District or admin2 equivalent area: \_\_\_\_\_

Sub-district or admin3 equivalent area: \_\_\_\_\_

Village, township or other: \_\_\_\_\_

Name and phone number of the community leader \_\_\_\_\_

Other land marks/boundary with/address: \_\_\_\_\_

Date & type of most recent WPV detected, province/district: \_\_\_\_\_

Date & type of most recent VDPV detected, province/district: \_\_\_\_\_

Date & type of most recent Sabine virus detected, province/district: \_\_\_\_\_

Date of tOPV-bOPV switch: \_\_\_\_\_

Date of most recent tOPV used through SIA: \_\_\_\_\_

Date of most recent mOPV2 used through SIA: \_\_\_\_\_

Current RI schedule: only OPV, only IPV, OPV+IPV

### **Geo location of the case or environmental site**

Latitude: \_\_\_\_\_ Longitude: \_\_\_\_\_

Map showing the location /Geo location

## 2. AFP case, contact or healthy person's detail

EPID number/other identifier: \_\_\_\_\_

Name: \_\_\_\_\_

Date of birth/Age (m): \_\_\_\_\_ Sex: \_\_\_\_\_

Date of onset of paralysis/weakness: \_\_\_\_\_

Site of paralysis/weakness (If AFP): Rt leg, Rt arm, Lt leg, Lt arm, Other \_\_\_\_\_

### Stool specimen details AFP case/contact/healthy persons

	AFP case	Contact (if positive for SL2)	Healthy person (if positive for SL2)
Date 1 <sup>st</sup> stool collection			
Date 2 <sup>nd</sup> stool collection			
Date 1 <sup>st</sup> stool sent to lab			
Date 2 <sup>nd</sup> stool sent to lab			
Date 1 <sup>st</sup> stool received by lab			
Date 2 <sup>nd</sup> stool received by lab			
Date lab result			
Viruses isolated			
Genetic sequencing (nucleotide difference)			

### Vaccination history of AFP case/contact/healthy person

		AFP case	Contact	Healthy person
Routine Immunization	Number of RI OPV doses			
	Number of RI IPV doses			
	Date most recent RI bOPV*			
	Date most recent RI tOPV*			
	Date of most recent IPV*			
	Name of RI centre			
SIAs (prior to stool collection)	Number of SIA doses			
	Date of most recent SIA			
	Date of most recent tOPV or mOPV2 SIA			
Total	Total number of OPV + IPV doses received (RI and SIA)			

\*Card or by recall

Primary Immunodeficiency (PID) Screening (Jeffrey Model Warning Signs)

	AFP Case	Contact	Healthy Individual
Four or more new ear infections within 1 year			
Two or more serious sinus infections within 1 year			
Two or more months of antibiotics with little effect			
Two or more pneumonias within 1 year			
Failure to gain weight or grow normally			
Recurrent, deep skin or organ abscesses			
Recent thrush in mouth or fungal infection on skin			
Need for intravenous antibiotics to clear infections			
Two or more deep-seated infections including septicaemia			
A family history of PI			
<b>Total</b>			

Travel history

Did the AFP case/contact/healthy individual travel 30 days prior to the onset of paralysis/weakness? **Yes/No**

If Yes, where? (Explain briefly and give dates as best as possible)

---

Has AFP case/contact/healthy individual travelled other areas since the onset of paralysis/weakness?

**Yes/No**

If Yes, where? (Explain briefly and give dates as best as possible)

---

Did any close family members travel outside of the local area 30 days before onset of paralysis? **Yes/No**

If Yes, where? (Explain briefly and give dates as best as possible)

---

Were there any recent visitors to the home from outside of the local area in the 30 days prior to the onset of paralysis? Including confirmed or suspected PID individual or IDPs visitor **Yes/No**

If Yes, from where? (Explain briefly and give dates as best as possible)

---

Others (neighbours or same community members, travel history of pattern, etc.):

---

---

---



### 3. Environmental sample site details

EPID number/Lab ID: \_\_\_\_\_  
 Name of the ES site: \_\_\_\_\_  
 Date when this ES started: \_\_\_\_\_  
 Frequency of the sample collection: \_\_\_\_\_  
 Method of collection: \_\_\_\_\_  
 What time of day the sample was collected (Morning, Afternoon): \_\_\_\_\_  
 Name of the sample collector: \_\_\_\_\_  
 Name of the supervisor: \_\_\_\_\_

Number of times in past 12 months PV isolated from this site: \_\_\_\_\_  
 Number of times in past 12 months NPEV isolated from this site: \_\_\_\_\_  
 Number of times in past 12 months Sabine virus isolated from this site: \_\_\_\_\_  
 Date of most recent isolation of PV with type: \_\_\_\_\_  
 Date of most recent Sabin virus isolated with type: \_\_\_\_\_

Areas that are drained to this site:

District	Sub-district	Village/settlement	Total population	High risk pop type (if)

Any social event that took place before the sample collection:  
 If yes, date and description: \_\_\_\_\_  
 \_\_\_\_\_

ES specimen details

Date of ES collection: \_\_\_\_\_  
 Date of ES sent to lab: \_\_\_\_\_  
 Date of ES received by lab: \_\_\_\_\_  
 Date of lab result: \_\_\_\_\_  
 Lab result: \_\_\_\_\_  
 Genetic sequencing information: \_\_\_\_\_

## 4. Search for any containment breach

If the SL2 isolation is found to be directly or indirectly related to a polio laboratory or any human laboratory or a vaccine production facility then a competent virologist, laboratory expert, containment expert should investigate the laboratory or the vaccine facility as applicable (a separate detailed technical investigation may be used as recommended by the GPLN or the containment group).

Findings:

---

---

---

## 5. Active case search summary

Active case search in the nearby health facility and in the community (use AFP case investigation form of the country to investigate a suspected AFP case found during the search attach a line list of the case(s).

Name of place where AFP case detected	EPID number	Name of AFP case	Date of birth /age	Sex	Date of onset	Date of investigation	Stool specimen collected?
PID* line list (if applicable)							
Name of place where PID case detected	EPID number	Name of PID case	Date of birth /age	Sex	Date of onset	Date of investigation	Stool specimen collected?

A separate case investigation form should be used for full investigation of a suspected AFP or PID case

\* Primary Immune Deficiency

## 6. tOPV & mOPV2 search summary

Conduct a search for tOPV and mOPV2 vaccine as applicable for the area and country including at the health facilities and storage facilities at all levels regardless of the location from where SL2 was isolated. Use a tool attached as Annex 1 to conduct a search for tOPV

Name of place where tOPV/mOPV2 found	tOPV/mOPV2	# unopened vial	# partially used vial	# empty vial	Remarks Observations on vaccine management in the facility in general and also for mOPV2 (if, stock register matched or not, etc.

## 7. Immunization coverage survey summary among children 6-59 months old

Use a tool attached as annex 2 to conduct the survey

Name of area /cluster	% children received $\geq 3$ OPV doses by card	% children received $\geq 3$ OPV doses by recall	% children received at least 1 IPV /fIPV dose by card	% children received at least 1 IPV /fIPV dose by recall	Remarks



9. Summary of main findings: *[provide bullet list of main findings]*

1. \_\_\_\_\_

2. \_\_\_\_\_

3. \_\_\_\_\_

4. \_\_\_\_\_

5. \_\_\_\_\_

**10. Conclusions:** *[provide bullet list of main conclusions, i.e. what can be learned, deducted and concluded by considering the key findings.]*

1. \_\_\_\_\_

2. \_\_\_\_\_

3. \_\_\_\_\_

4. \_\_\_\_\_

5. \_\_\_\_\_



## 11. Recommendations and next steps:

1. \_\_\_\_\_

2. \_\_\_\_\_

3. \_\_\_\_\_

4. \_\_\_\_\_

5. \_\_\_\_\_

Annex 1: tOPV & mOPV2 search survey tool (use one form for each site)

Country \_\_\_\_\_ Province \_\_\_\_\_  
 District \_\_\_\_\_ Sub district \_\_\_\_\_  
 Type of facility:  Health care facility  vaccination centre  medicine shop  vaccine storage facility  
 other (specify) \_\_\_\_\_  
 Name and address of the facility: \_\_\_\_\_  
 Name & designation of the contact person or person interviewed: \_\_\_\_\_

	# un-opened vial	# partially used vial	# empty vial
# tOPV / mOPV2 vial found (circle)			
# of total doses found			
Vial stored in a cold chain? Yes/no			
If not in cold chain, how it is stored?			
VVM status of the vial (good/bad)			
Manufacturer of the vaccine			
Date of received of the vaccine			
Source of the vaccine (Government supply, private market)			
Reason for not disposing			
Is the authority willing to dispose the vaccine now?			
Has the vaccine been disposed as per WHO guide*? yes/no			
If disposed, what method used?			
Persons, designation , signature who witnessed of disposal (if)			
1.			
2.			
3.			
Has any compensation given? Two bOPV doses for each tOPV /mOPV2 dose or other, mention, Yes/no			
Has any certification of disposal been given? Yes/no			

\*How to handle & dispose tOPV :

[http://www.who.int/immunization/diseases/poliomyelitis/endgame\\_objective2/oral\\_polio\\_vaccine/SOPs\\_tOPV\\_found\\_after\\_the\\_switch\\_July2016.pdf](http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/SOPs_tOPV_found_after_the_switch_July2016.pdf)





[www.polioeradication.org](http://www.polioeradication.org)